Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ:CARA opened at $5.07 on Friday. Cara Therapeutics has a one year low of $2.71 and a one year high of $11.39. The company has a market cap of $23.19 million, a P/E ratio of -0.24 and a beta of 0.50. The firm’s fifty day moving average price is $5.08 and its two-hundred day moving average price is $4.26.

Institutional Trading of Cara Therapeutics

Several institutional investors have recently added to or reduced their stakes in CARA. FMR LLC raised its stake in Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Cara Therapeutics in the 4th quarter valued at $953,000. XTX Topco Ltd acquired a new position in shares of Cara Therapeutics during the 3rd quarter worth $29,000. Shay Capital LLC bought a new position in shares of Cara Therapeutics in the fourth quarter worth about $524,000. Finally, Curi RMB Capital LLC bought a new position in Cara Therapeutics in the 4th quarter valued at approximately $277,000. 44.66% of the stock is currently owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.